Oxford Biomedica changes management
Former Rentschler-CEO Dr Frank Mathias officially takes up his new position as CEO and board member of Oxford Biomedica at the end of March.
ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 194 entries already.
Former Rentschler-CEO Dr Frank Mathias officially takes up his new position as CEO and board member of Oxford Biomedica at the end of March.
Dr Mark Chadwick will bring extensive industry knowledge to his new role as Strategic Business Advisor at UK-based Ingenza Ltd.
France-based Abivax SA announced the appointment of Sheldon Sloan, M.D., M. Bioethics, as its new Chief Medical Officer. He will assume the new role in the beginning of March.
Dr Carole Nicco took up her position as CSO of Belgium-based BioSenic in mid-January. Nicco will oversee the development of BioSenic’s cell therapy and autoimmune disease platform pipeline and be responsible for R&D programmes.
At the beginning of January 2023?Marjut Falkstedt will start as new Chief Executive of the European Investment Fund (EIF).
Biotechnology was dramatically rewarded in the financial markets through much of 2020 and the first half of 2021, widely credited for providing the COVID-19 vaccines. This followed four already exceptional years in the financial markets, with the Nasdaq Biotech Index (NBI) hitting its all-time high of 5449.32 on 30 August 2021.
Valneva has appointed Dipal Patel as new Chief Commercial Officer and Management Board member.
Our species – modern humans, or homo sapiens sapiens – has ever striven for progress. And progress was greatly enabled by fire, a fundamental chemical phenomenon that allows the fast release of large amounts of energy.
Dr Frank Mathias, currently CEO at Rentschler Biopharma, will join Oxford Biomedica as CEO and Board Director in March 2023.
At the beginning of november, OxSonics Therapeutics has appointed Jérôme Marzinski as its Chief Executive Officer.